Multi MERCI
Mechanical Thrombectomy for Acute Ischemic Stroke: Final Results of the Multi MERCI Trial
Clinical Question
To evaluate if a newer generation mechanical thrombectomy device (L5 Retriever) could improve recanalization rates and to assess the safety of mechanical thrombectomy in patients with acute large vessel occlusion stroke within 8 hours of onset, including those who had persistent occlusion after receiving intravenous tPA.
Bottom Line
The newer generation L5 Retriever was associated with numerically higher rates of recanalization compared to first-generation devices, although the difference was not statistically significant. Successful vascular recanalization, by any method, was strongly associated with improved functional outcomes and lower mortality at 90 days. Performing thrombectomy after IV tPA did not increase complications.
Major Points
- Multi MERCI was a prospective, single-arm, international, multicenter trial that enrolled 164 patients with large vessel occlusion stroke who were treated within 8 hours of symptom onset.
- The study included a cohort of patients (29%) who had persistent vessel occlusions after treatment with IV tissue plasminogen activator (tPA).
- The newer L5 Retriever device achieved successful recanalization (TIMI II or III flow) in 57.3% of cases. The overall final recanalization rate after all interventions (including adjunctive intra-arterial tPA) was 68%.
- A good clinical outcome (mRS 0-2) at 90 days was achieved in 36% of all patients, and was significantly more likely in patients with successful recanalization (49% vs. 9.6%; P<0.001).
- Mortality at 90 days was 34% overall, and was significantly lower in patients with successful recanalization (25% vs. 52%; P<0.001).
- The rate of symptomatic intracranial hemorrhage was 9.8%, and the rate of clinically significant procedural complications was 5.5%.
Design
Study Type: International, multicenter, prospective, single-arm trial
Randomization:
Blinding: This was an open-label, single-arm study. Angiographic outcomes were determined by unblinded local investigators. A central core lab reviewed imaging for hemorrhages, which were adjudicated by an independent data safety monitoring board (DSMB).
Enrollment Period: January 2004 to July 2006
Follow-up Duration: 90 days
Centers: 15
Countries: United States, Canada
Sample Size: 164
Analysis: The primary outcome was the recanalization rate with the L5 Retriever device, compared against a prespecified performance goal. Secondary outcomes compared recanalized vs. non-recanalized patients using Fisher exact test.
Inclusion Criteria
- Age ≥18 years
- National Institutes of Health Stroke Scale (NIHSS) score ≥8
- Stroke symptom onset within 8 hours
- Angiographically confirmed occlusion of a treatable large vessel (ICA, M1, M2, vertebral, or basilar artery)
- Included patients who had persistent occlusion after receiving IV tPA
Exclusion Criteria
- Inability to obtain informed consent
- Current pregnancy
- Serum glucose <50 mg/dL
- Oral anticoagulation with international normalized ratio (INR) >3.0
- Platelet count <30,000/μL
- Sustained systolic blood pressure >185 mm Hg or diastolic >110 mm Hg
Baseline Characteristics
| Characteristic | Control | Active |
|---|---|---|
| Group | Overall Population (n=164) | |
| Age, mean±SD, years | 68.1±16.0 | |
| Female, % | 57 | |
| Baseline NIHSS, median (interquartile range) | 19 (15-23) | |
| IV tPA pretreatment, % | 29 | |
| Site of occlusion - Middle cerebral artery, % | 60 | |
| Symptom onset to groin puncture, median hours (IQR) | 4.3 (3.2-5.3) |
Arms
| Field | Mechanical Thrombectomy |
|---|---|
| Intervention | Mechanical thrombectomy using a Merci Retriever device (X5, X6, or L5). Adjunctive intra-arterial tPA was permitted if device-only thrombectomy failed. |
| Duration | Single procedure |
Outcomes
| Outcome | Type | Control | Intervention | HR / OR / RR | P-value |
|---|---|---|---|---|---|
| Successful recanalization (TIMI grade II or III flow) of the target vessel after treatment with the L5 Retriever device alone. | Primary | 57.3% (75/131) | Met prespecified non-inferiority goal of ≥44% | ||
| Favorable outcome (mRS ≤2) at 90 days | Secondary | 9.6% (Not Recanalized) | 49% (Recanalized) | RR 5.1 (95% CI, 2.2-12) | <0.001 |
| Mortality at 90 days | Secondary | 52% (Not Recanalized) | 25% (Recanalized) | RR 0.48 (95% CI, 0.31-0.73) | <0.001 |
| Overall final recanalization rate (all devices and adjunctive therapies) | Secondary | 68% (95% CI, 61-75) | |||
| Symptomatic intracranial hemorrhage | Adverse | 9.8% (16/164) | |||
| Symptomatic PH-2 hemorrhage | Adverse | 2.4% (4/164) | |||
| Clinically significant procedural complications | Adverse | 5.5% (9/164) | |||
| Device-related serious adverse events | Adverse | 2.4% |
Subgroup Analysis
There were no significant differences in rates of intracranial hemorrhage or procedural complications between patients who received prior IV tPA and those who did not.
Criticisms
- The trial was a single-arm study without a contemporaneous control group, making it impossible to definitively conclude that thrombectomy improved outcomes over medical management alone.
- The angiographic outcomes (recanalization) were interpreted by unblinded site investigators rather than a blinded central core lab, which could introduce bias.
- The study enrolled a heterogeneous population with no upper limits on age or stroke severity, making direct mortality comparisons with other trials difficult.
Funding
Concentric Medical, Inc.
Based on: Multi MERCI (Stroke, 2008)
Authors: Wade S. Smith, MD, PhD; Gene Sung, ..., MD; for the Multi MERCI Investigators
Citation: Stroke. 2008;39:1205-1212.
Content summarized and formatted by NeuroTrials.ai.